Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Importance Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic
drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but …

Colorectal cancer is a heterogeneous disease that develops via stepwise accumulation of
well-characterized genetic and epigenetic alterations. We review the genetic changes …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Ovarian cancer is known as a serious malignancy that affects women's reproductive tract
and can considerably threat their health. A wide range of molecular mechanisms and …

Colorectal cancer (CRC) results from the progressive accumulation of multiple genetic and
epigenetic aberrations within cells. The progression from colorectal adenoma to carcinoma …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

Colorectal cancer (CRC) is a leading cause of death among cancer patients. This
heterogeneous disease is characterized by alterations in multiple molecular pathways …